Related Experiment Video

Updated: Jun 16, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Molecular bases of liver cancer refractoriness to pharmacological treatment

J J G Marin1, M R Romero, O Briz

  • 1Laboratory of Experimental Hepatology and Drug Targeting, University Hospital of Salamanca, Biomedical Research Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), University of Salamanca, Salamanca, Spain. jjgmarin@usal.es

Current Medicinal Chemistry
|January 22, 2010
PubMed

Insights

Hepatocellular carcinoma and cholangiocarcinoma exhibit poor drug response due to chemoresistance mechanisms. Understanding these molecular bases is crucial for developing novel liver cancer treatments.

Area of Science:

  • Hepatology
  • Oncology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are primary liver cancers.
  • These cancers show limited response to current pharmacological treatments.
  • Drug refractoriness can be inherent or develop during treatment.

Purpose of the Study:

  • To review mechanisms of chemoresistance in HCC and CCA.
  • To examine how these mechanisms affect various drug classes used for liver cancer.
  • To highlight the need for understanding molecular bases of drug resistance.

Main Methods:

  • Literature review of drug resistance mechanisms in liver cancer.
  • Analysis of chemoresistance pathways affecting current and historical therapies.
  • Synthesis of information on molecular targets and signaling pathways.

Main Results:

  • Common chemoresistance mechanisms include reduced drug uptake, enhanced drug export, and altered molecular targets.
  • Cancer cells develop resistance through intracellular drug inactivation and enhanced DNA repair.
  • Dysregulation of signaling pathways impacts tumor cell apoptosis and survival balance.

Conclusions:

  • Chemoresistance significantly limits the efficacy of anticancer drugs for HCC and CCA.
  • A deeper understanding of molecular resistance mechanisms is essential.
  • Novel drugs and pharmacological strategies are needed to overcome drug refractoriness in liver cancer.

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

The Influence of Liver Resection on Intrahepatic Tumor Growth07:55

The Influence of Liver Resection on Intrahepatic Tumor Growth

Published on: April 9, 2016

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...